Labcorp Holdings (LSE:0JSY) - Hisse Senedi Fiyatı, Haberler ve Analizler

0JSY Stoklara Genel Bakış

Labcorp Holdings Inc. laboratuvar hizmetleri sunmaktadır. Daha fazla detay

0JSY temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	0/6
Finansal Sağlık	4/6
Temettüler	2/6

Ödüller

Adil değer tahminimizden 67.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 20.56% oranında artması öngörülüyor

Risk Analizi

Yüksek borç seviyesine sahip

Finansal sonuçları etkileyen büyük tek seferlik kalemler

Labcorp Holdings Inc. Rakipler

Integrated Diagnostics Holdings

LSE:IDHC

US$229.9m

Smith & Nephew

LSE:SN.

UK£8.6b

Mediclinic International

LSE:MDC

UK£3.7b

ConvaTec Group

LSE:CTEC

UK£4.8b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Labcorp Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$239.82
52 Haftanın En Yüksek Seviyesi	US$248.07
52 Haftanın En Düşük Seviyesi	US$192.43
Beta	1.04
11 Aylık Değişim	4.75%
3 Aylık Değişim	3.42%
1 Yıllık Değişim	12.96%
33 Yıllık Değişim	-17.73%
5 Yıllık Değişim	38.47%
Halka arzdan bu yana değişim	35.94%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	0JSY	GB Healthcare	GB Pazar
7D	2.7%	0.6%	2.2%
1Y	13.0%	-22.6%	8.0%

Getiri vs. Endüstri: 0JSY geçen yıl % -22.6 oranında getiri sağlayan UK Healthcare sektörünü aştı.

Getiri vs Piyasa: 0JSY geçen yıl % 8 oranında getiri sağlayan UK Piyasasını aştı.

Fiyat Oynaklığı

Is 0JSY's price volatile compared to industry and market?
0JSY volatility
0JSY Average Weekly Movement	2.9%
Healthcare Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 0JSY son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 0JSY 'nin haftalık oynaklığı ( 3% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1995	61,975	Adam Schechter	www.labcorp.com

Labcorp Holdings Inc. laboratuvar hizmetleri sunmaktadır. Teşhis Laboratuvarları ve Biyofarma Laboratuvar Hizmetleri olmak üzere iki segmentte faaliyet göstermektedir. Şirket kan kimyası analizleri, idrar analizleri, kan hücresi sayımı, tiroid, PAP, hemoglobin A1C ve D vitamini, prostat spesifik antijenler, cinsel yolla bulaşan hastalıklar, hepatit C, mikrobiyoloji kültürleri ve prosedürleri ile alkol ve diğer madde bağımlılığı testleri gibi çeşitli testler sunmaktadır.

Labcorp Holdings Inc. Temel Bilgiler Özeti

Labcorp Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
0JSY temel i̇stati̇sti̇kler
Piyasa değeri	US$20.05b
Kazançlar(TTM)	US$435.50m
Gelir(TTM)	US$12.71b

46.0x

F/K Oranı

1.6x

P/S Oranı

0JSY aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
0JSY gelir tablosu (TTM)
Gelir	US$12.71b
Gelir Maliyeti	US$9.16b
Brüt Kâr	US$3.55b
Diğer Giderler	US$3.11b
Kazançlar	US$435.50m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	5.21
Brüt Marj	27.92%
Net Kâr Marjı	3.43%
Borç/Özkaynak Oranı	83.2%

0JSY uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

1.2%

Mevcut Temettü Verimi

56%

Ödeme Oranı

0JSY güvenilir bir temettü ödüyor mu?

0JSY temettü geçmişine ve kıyaslamalara bakın

Yaklaşan bir temettüyü almak için ne zaman 0JSY satın almanız gerekir?
Labcorp Holdings temettü tari̇hleri̇
Eski Temettü Tarihi	Nov 26 2024
Temettü Ödeme Tarihi	Dec 13 2024
Eski temettüye kadar geçen günler	2 days
Temettü ödeme tarihine kadar geçen günler	19 days

0JSY güvenilir bir temettü ödüyor mu?

0JSY temettü geçmişine ve kıyaslamalara bakın

0JSY Stoklara Genel Bakış

Ödüller

Risk Analizi

Labcorp Holdings Inc. Rakipler

LSE:IDHC

US$229.9m

LSE:SN.

UK£8.6b

LSE:MDC

UK£3.7b

LSE:CTEC

UK£4.8b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Upcoming dividend of US$0.72 per share

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Recent updates

Labcorp Holdings Inc. Announces Chief Financial Officer Changes

Upcoming dividend of US$0.72 per share

Third quarter 2024 earnings released: EPS: US$2.02 (vs US$2.12 in 3Q 2023)

Labcorp Holdings Inc. Updates Earnings Guidance for the Year 2024

Labcorp Expands Sexually Transmitted Infection Test Offerings with Rapid Syphilis Test

Labcorp Holdings Inc. to Report Q3, 2024 Results on Oct 24, 2024

Labcorp Holdings Inc. (NYSE:LH) agreed to acquire 15% stake in SYNLAB AG (HMSE:SYAB) from Cinven Limited for €140 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of an Asset Purchase Agreement to acquire Select Assets of BioReference Health, LLC for approximately $240 million.

Upcoming dividend of US$0.72 per share

CFO & Executive VP recently sold US$3.4m worth of stock

Insider recently sold US$2.8m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Substantially all Assets of Invitae Corporation (OTCPK:NVTA.Q).

Labcorp Holdings Inc. Receives FDA De Novo Marketing Authorization for Pgdx Elio™ Plasma Focus Dx

Second quarter 2024 earnings released: EPS: US$2.44 (vs US$1.75 in 2Q 2023)

Labcorp Holdings Inc. Revises Financial Guidance for the Full Year 2024

Labcorp Declares Quarterly Cash Dividend, Payable on September 13, 2024

Labcorp Holdings Inc. to Report Q2, 2024 Results on Aug 01, 2024

Labcorp Launches Labcorp Global Trial Connect to Accelerate Clinical Trials

Labcorp Holdings Inc. Announces New Strategic Service Offerings Within Precision Oncology Portfolio

Upcoming dividend of US$0.72 per share

Labcorp Introduces First Trimester Screening Test to Assess Preeclampsia Risk During Pregnancy

Labcorp Receives FDA Approval for First Companion Diagnostic for Use with Pfizer's Newly Approved Gene Therapy to Treat Patients with Hemophilia B

First quarter 2024 earnings released: EPS: US$2.71 (vs US$2.35 in 1Q 2023)

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Labcorp Announces First-of-Its-Kind Test for Early Indication of Neurodegenerative Diseases and Brain Injuries Using a Blood Draw

Dividend of US$0.72 announced

Labcorp Declares Quarterly Dividend, Payable on June 12, 2024

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Laboratory Corporation of America Holdings, Annual General Meeting, May 14, 2024

Labcorp to Present Diverse Portfolio of Precision Oncology Research at the Annual Meeting of the American Association for Cancer Research

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Laboratory Corporation of America Holdings to Report Q1, 2024 Results on Apr 25, 2024

Labcorp Launches pTau217 Blood Biomarker Test to Accelerate Path to Diagnosis of Alzheimer's Disease and Support Clinical Trials

Labcorp Launches Weight Loss Management Testing Solutions

CFO & Executive VP recently sold US$4.4m worth of stock

Upcoming dividend of US$0.72 per share

Full year 2023 earnings released: EPS: US$4.35 (vs US$14.04 in FY 2022)

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on March 13, 2024

Labcorp Announces the Launch and Availability of A New, FDA-Cleared Blood Test for Risk Assessment and Clinical Management of Severe Preeclampsia

Laboratory Corporation of America Holdings to Report Q4, 2023 Results on Feb 15, 2024

Labcorp Declares Quarterly Cash Dividend, Payable on March 13, 2024

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory business from Legacy Health System Insurance Company.

Geneoscopy, Inc. Signs Multi-Year Agreement with Labcorp to Distribute Noninvasive Multi-Target Stool Rna (Mt-Srna) Colorectal Cancer Screening Test

Upcoming dividend of US$0.72 per share at 1.5% yield

Third quarter 2023 earnings released: EPS: US$2.12 (vs US$3.91 in 3Q 2022)

Labcorp Declares a Cash Dividend, Payable on December 12, 2023

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Outreach Laboratory Business of Baystate Health, Inc.

Laboratory Corporation of America Holdings to Report Q3, 2023 Results on Oct 26, 2023

Independent Director recently sold US$1.1m worth of stock

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach Laboratory Business and Select Operating Assets from Tufts Medicine, Inc.

Upcoming dividend of US$0.72 per share at 1.3% yield

Laboratory Corporation of America Holdings Announces Quarterly Cash Dividend, Payable on September 8, 2023

Second quarter 2023 earnings released: EPS: US$1.75 (vs US$3.89 in 2Q 2022)

Laboratory Corporation of America Holdings acquired Clinical Laboratory Division from Enzo Biochem, Inc. for approximately $115 million.

Laboratory Corporation of America Holdings (NYSE:LH) completed the acquisition of Outreach laboratory services assets of Jefferson Health.

Laboratory Corporation of America Holdings (NYSE:LH) entered into an agreement to acquire Outreach laboratory business from Legacy Health System Insurance Company.

Laboratory Corporation of America Holdings to Report Q2, 2023 Results on Jul 27, 2023

Laboratory Corporation of America Holdings Appoints Paul B. Rothman as a Member of the Board

Laboratory Corporation of America Holdings Launches Labcorp Plasma Focus